N6-methyladenosine (m⁶A) is a common post-transcriptional modification on messenger and non-coding RNAs (an epitranscriptomic mark) [4]. The m⁶A mark is recognised by the YTH domain containing family proteins YTHDC1-2 and YTHDF1-3 (in humans), and regulates RNA biogenesis, stability and splicing functions, which exert effects on gene expression programmes and biological processes. Defects in the RNA regulatory system (writers, readers, erasers) are associated with human diseases, including cancer [1-3]. Epitranscriptomic regulators offer molecular targets with therapeutic potential.

1. Adamopoulos PG, Athanasopoulou K, Daneva GN, Scorilas A. (2023) The Repertoire of RNA Modifications Orchestrates a Plethora of Cellular Responses. Int J Mol Sci, 24 (3). [PMID:36768716]

2. Nombela P, Miguel-López B, Blanco S. (2021) The role of m⁶A, m⁵C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer, 20 (1): 18. [PMID:33461542]

3. Teng PC, Liang Y, Yarmishyn AA, Hsiao YJ, Lin TY, Lin TW, Teng YC, Yang YP, Wang ML, Chien CS et al.. (2021) RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases. Int J Mol Sci, 22 (19). [PMID:34638933]

4. Yang Y, Hsu PJ, Chen YS, Yang YG. (2018) Dynamic transcriptomic m⁶A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res, 28 (6): 616-624. [PMID:29789545]

5. Zálešák F, Nai F, Herok M, Bochenkova E, Bedi RK, Li Y, Errani F, Caflisch A. (2024) Structure-Based Design of a Potent and Selective YTHDC1 Ligand. J Med Chem, 67 (11): 9516-9535. [PMID:38787793]